Epizyme’s EZH2 inhibitor gains two approvals in quick succession — a milestone for this new class of epigenetic cancer drug that targets histone marks with greater precision than previous generations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Emerging role of G9a in cancer stemness and promises as a therapeutic target
Oncogenesis Open Access 13 November 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
14 August 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41587-020-0672-3
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Histone-writer cancer drugs enter center stage. Nat Biotechnol 38, 909–912 (2020). https://doi.org/10.1038/s41587-020-0621-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0621-1
This article is cited by
-
Structural classification of EZH2 inhibitors and prospects for the treatment of tumor: a review
Medicinal Chemistry Research (2023)
-
Emerging role of G9a in cancer stemness and promises as a therapeutic target
Oncogenesis (2021)
-
A PRC1–RNF2 knockout punch for cancer
Nature Cancer (2021)